{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T12:01:07Z","timestamp":1772366467735,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-024-10963-6","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T01:02:06Z","timestamp":1723683726000},"page":"806-814","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Are there features that can predict the unresectability of pleural mesothelioma?"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0108-3226","authenticated-orcid":false,"given":"Maria","family":"Mayoral","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Arimateia Batista","family":"Araujo-Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay See","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasad S.","family":"Adusumilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Rusch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjorie","family":"Zauderer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle S.","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"key":"10963_CR1","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jtho.2021.12.014","volume":"17","author":"JL Sauter","year":"2022","unstructured":"Sauter JL, Dacic S, Galateau-Salle F et al (2022) The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification. J Thorac Oncol 17:608\u2013622. https:\/\/doi.org\/10.1016\/j.jtho.2021.12.014","journal-title":"J Thorac Oncol"},{"key":"10963_CR2","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.21037\/tlcr.2019.11.11","volume":"9","author":"N Alpert","year":"2020","unstructured":"Alpert N, van Gerwen M, Taioli E (2020) Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted\/banned asbestos use. Transl Lung Cancer Res 9:S28\u2013S38. https:\/\/doi.org\/10.21037\/tlcr.2019.11.11","journal-title":"Transl Lung Cancer Res"},{"key":"10963_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11864-008-0067-z","volume":"9","author":"H Yang","year":"2008","unstructured":"Yang H, Testa JR, Carbone M (2008) Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol 9:147\u2013157. https:\/\/doi.org\/10.1007\/s11864-008-0067-z","journal-title":"Curr Treat Options Oncol"},{"key":"10963_CR4","doi-asserted-by":"publisher","first-page":"12208","DOI":"10.1002\/cam4.5915","volume":"12","author":"P Bou-Samra","year":"2023","unstructured":"Bou-Samra P, Chang A, Azari F et al (2023) Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: a review of the National Cancer Database. Cancer Med 12:12208\u201312220. https:\/\/doi.org\/10.1002\/cam4.5915","journal-title":"Cancer Med"},{"key":"10963_CR5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.21037\/tlcr.2018.07.05","volume":"7","author":"L Berzenji","year":"2018","unstructured":"Berzenji L, Van Schil PE, Carp L (2018) The eighth TNM classification for malignant pleural mesothelioma. Transl Lung Cancer Res 7:543\u2013549. https:\/\/doi.org\/10.21037\/tlcr.2018.07.05","journal-title":"Transl Lung Cancer Res"},{"key":"10963_CR6","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/j.ejcts.2009.12.039","volume":"37","author":"A Nakas","year":"2010","unstructured":"Nakas A, Black E, Entwisle J, Muller S, Waller DA (2010) Surgical assessment of malignant pleural mesothelioma: have we reached a critical stage? Eur J Cardiothorac Surg 37:1457\u20131463. https:\/\/doi.org\/10.1016\/j.ejcts.2009.12.039","journal-title":"Eur J Cardiothorac Surg"},{"key":"10963_CR7","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1016\/j.jtho.2016.08.147","volume":"11","author":"AK Nowak","year":"2016","unstructured":"Nowak AK, Chansky K, Rice DC et al (2016) The IASLC Mesothelioma Staging Project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma. J Thorac Oncol 11:2089\u20132099. https:\/\/doi.org\/10.1016\/j.jtho.2016.08.147","journal-title":"J Thorac Oncol"},{"key":"10963_CR8","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jtcvs.2018.09.106","volume":"157","author":"M Hashimoto","year":"2019","unstructured":"Hashimoto M, Takeuchi J, Takuwa T et al (2019) Pleural thickness after neoadjuvant chemotherapy is a prognostic factor in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 157:404\u2013413. https:\/\/doi.org\/10.1016\/j.jtcvs.2018.09.106","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10963_CR9","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ejrad.2009.02.002","volume":"74","author":"G Ak","year":"2010","unstructured":"Ak G, Metintas M, Metintas S, Yildirim H, Ozkan R, Ozden H (2010) Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma. Eur J Radiol 74:130\u2013135. https:\/\/doi.org\/10.1016\/j.ejrad.2009.02.002","journal-title":"Eur J Radiol"},{"key":"10963_CR10","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.jtho.2016.04.027","volume":"11","author":"RR Gill","year":"2016","unstructured":"Gill RR, Naidich DP, Mitchell A et al (2016) North American Multicenter Volumetric CT Study for clinical staging of malignant pleural mesothelioma: feasibility and logistics of setting up a quantitative imaging study. J Thorac Oncol 11:1335\u20131344. https:\/\/doi.org\/10.1016\/j.jtho.2016.04.027","journal-title":"J Thorac Oncol"},{"key":"10963_CR11","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.athoracsur.2016.06.069","volume":"102","author":"VW Rusch","year":"2016","unstructured":"Rusch VW, Gill R, Mitchell A et al (2016) A multicenter study of volumetric computed tomography for staging malignant pleural mesothelioma. Ann Thorac Surg 102:1059\u20131066. https:\/\/doi.org\/10.1016\/j.athoracsur.2016.06.069","journal-title":"Ann Thorac Surg"},{"key":"10963_CR12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1183\/09031936.00146110","volume":"38","author":"T Frauenfelder","year":"2011","unstructured":"Frauenfelder T, Tutic M, Weder W et al (2011) Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma? Eur Respir J 38:162\u2013168. https:\/\/doi.org\/10.1183\/09031936.00146110","journal-title":"Eur Respir J"},{"key":"10963_CR13","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S0022-5223(98)70274-0","volume":"115","author":"HI Pass","year":"1998","unstructured":"Pass HI, Temeck BK, Kranda K, Steinberg SM, Feuerstein IR (1998) Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 115:310\u2013317. https:\/\/doi.org\/10.1016\/S0022-5223(98)70274-0","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10963_CR14","doi-asserted-by":"publisher","unstructured":"De Perrot M, Dong Z, Bradbury P et al (2017) Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma. Eur Respir J 49:1601428. https:\/\/doi.org\/10.1183\/13993003.01428-2016","DOI":"10.1183\/13993003.01428-2016"},{"key":"10963_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40644-021-00415-5","volume":"21","author":"O Lauk","year":"2021","unstructured":"Lauk O, Patella M, Neuer T et al (2021) Implementing CT tumor volume and CT pleural thickness into future staging systems for malignant pleural mesothelioma. Cancer Imaging 21:1\u20138. https:\/\/doi.org\/10.1186\/s40644-021-00415-5","journal-title":"Cancer Imaging"},{"key":"10963_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-022-02482-5","volume":"22","author":"W Wen","year":"2022","unstructured":"Wen W, Xu D, Piao Y, Li X (2022) Prognostic value of maximum standard uptake value, metabolic tumour volume, and total lesion glycolysis of 18F-FDG PET\/CT in patients with malignant pleural mesothelioma: a systematic review and meta-analysis. Cancer Cell Int 22:1\u201312. https:\/\/doi.org\/10.1186\/s12935-022-02482-5","journal-title":"Cancer Cell Int"},{"key":"10963_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","volume":"33","author":"S Popat","year":"2022","unstructured":"Popat S, Baas P, Faivre-Finn C et al (2022) Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 33:129\u2013142. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.005","journal-title":"Ann Oncol"},{"key":"10963_CR18","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.jtho.2019.04.029","volume":"14","author":"JS Friedberg","year":"2019","unstructured":"Friedberg JS, Culligan MJ, Tsao AS et al (2019) A proposed system toward standardizing surgical-based treatments for malignant pleural mesothelioma, from the Joint National Cancer Institute\u2013International Association for the Study of Lung Cancer\u2013Mesothelioma Applied Research Foundation Taskforce. J Thorac Oncol 14:1343\u20131353. https:\/\/doi.org\/10.1016\/j.jtho.2019.04.029","journal-title":"J Thorac Oncol"},{"key":"10963_CR19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/J.JTHO.2015.11.005","volume":"11","author":"F Galateau-Salle","year":"2016","unstructured":"Galateau-Salle F, Churg A, Roggli V, Travis WD (2016) The 2015 World Health Organization Classification of tumors of the pleura: advances since the 2004 classification. J Thorac Oncol 11:142\u2013154. https:\/\/doi.org\/10.1016\/J.JTHO.2015.11.005","journal-title":"J Thorac Oncol"},{"key":"10963_CR20","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/bmj.309.6948.188","volume":"309","author":"DG Altman","year":"1994","unstructured":"Altman DG, Bland JM (1994) Statistics notes: diagnostic tests 3: receiver operating characteristic plots. Br Med J 309:188. https:\/\/doi.org\/10.1136\/bmj.309.6948.188","journal-title":"Br Med J"},{"key":"10963_CR21","doi-asserted-by":"publisher","unstructured":"Kidd AC, Anderson O, Cowell GW et al (2022) Fully automated volumetric measurement of malignant pleural mesothelioma by deep learning AI: validation and comparison with modified RECIST response criteria. Thorax 77:1251\u20131259. https:\/\/doi.org\/10.1136\/thoraxjnl-2021-217808","DOI":"10.1136\/thoraxjnl-2021-217808"},{"key":"10963_CR22","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1245\/s10434-022-12790-9","volume":"30","author":"T Ito","year":"2023","unstructured":"Ito T, Nakamura S, Kadomatsu Y et al (2023) Impact of pleural thickness on occurrence of postoperative complications in patients with malignant pleural mesothelioma. Ann Surg Oncol 30:1574\u20131583. https:\/\/doi.org\/10.1245\/s10434-022-12790-9","journal-title":"Ann Surg Oncol"},{"key":"10963_CR23","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.athoracsur.2014.09.056","volume":"99","author":"E Taioli","year":"2015","unstructured":"Taioli E, Wolf AS, Flores RM (2015) Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma. Ann Thorac Surg 99:472\u2013480. https:\/\/doi.org\/10.1016\/j.athoracsur.2014.09.056","journal-title":"Ann Thorac Surg"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-10963-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-024-10963-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-10963-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T12:10:58Z","timestamp":1746447058000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-024-10963-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["10963"],"URL":"https:\/\/doi.org\/10.1007\/s00330-024-10963-6","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,15]]},"assertion":[{"value":"9 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Michelle S. Ginsberg.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"Dr. Mayoral received funding from Canon Spain to attend the Annual Meeting of the Radiological Society of North America (RSNA) in 2023 to present an oral communication on the results of this manuscript. Dr. Adusumilli declares research funding from ATARA Biotherapeutics; Scientific Advisory Board Member and Consultant for ATARA Biotherapeutics, Bayer, Bio4T2, Carisma Therapeutics, Imugene, ImmPactBio, Johnston & Johnston, Orion pharma, Outpace Bio; Patents, royalties, and intellectual property on mesothelin-targeted CAR and other T-cell therapies, which have been licensed to ATARA Biotherapeutics, issued patent method for detection of cancer cells using virus, and pending patent applications on PD-1 dominant negative receptor, wireless pulse-oximetry device, and on an ex vivo malignant pleural effusion culture system. Memorial Sloan Kettering Cancer Center has licensed intellectual property related to mesothelin-targeted CARs and T-cell therapies to ATARA Biotherapeutics and has associated financial interests. Dr. Adusumilli\u2019s laboratory work is supported by grants from the National Institutes of Health (P30 CA008748, R01 CA236615-01, and R01 CA235667), the U.S. Department of Defense (BC132124, LC160212, CA170630, CA180889, and CA200437), the Batishwa Fellowship, the Comedy vs. Cancer Award, the Dalle Pezze Foundation, the Derfner Foundation, the Esophageal Cancer Education Fund, the Geoffrey Beene Foundation, the Memorial Sloan Kettering Technology Development Fund, the Miner Fund for Mesothelioma Research, Mr. William H. Goodwin and Alice Goodwin, the Commonwealth Foundation for Cancer Research, and the Experimental Therapeutics Center of Memorial Sloan Kettering Cancer Center. P.S.A.\u2019s laboratory receives research support from Atara Biotherapeutics. Dr. Rusch\u2019s conflicts of interest related to the content of this manuscript are being a member of the DSMC for the MARS II trial and RAMON trial, Cancer Research UK (unpaid), and being co-chair of the Thoracic Malignancy Steering Committee, NIH (payment for meeting preparation). Dr. Zauderer has received in the last 3 years consulting fees from Curis, Ikena, Takeda, GlaxoSmithKline, and Novocure and honoraria for CME content from PER, Medscape, and Research to Practice. Memorial Sloan Kettering receives research funding from the Department of Defense, the National Institutes of Health, MedImmune, Precog, GlaxoSmithKline, Epizyme, Polaris, Sellas Life Sciences, Bristol Myers Squibb, Millenium\/Takeda, Curis, and Atara for research conducted by Dr. Zauderer. Dr. Zauderer serves as Chair of the Board of Directors of the Mesothelioma Applied Research Foundation, uncompensated.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Dr. Tan performed the statistical analysis of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None of the study subjects or cohorts have been previously reported; there are no overlaps with any prior studies.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}